Built on the ZEISS Health Data Platform, ZEISS Collaborative Care offers eye care professionals a flexible way to collaborate – whether as a standalone cloud application or as an integrated extension of ZEISS FORUM – enabling secure data sharing, structured referrals, and real-time clinical coordination to strengthen continuity of care across the ophthalmic workflow.

JENA, Germany, Feb. 23, 2026 /PRNewswire/ — ZEISS Medical Technology, one of the world’s leading medical technology companies, today launched its ZEISS Collaborative Care browser-based software application enabling eye care professionals to seamlessly work together securely sharing data, referring patients, and strengthening their professional networks. The new solution addresses longstanding challenges in ophthalmic care, particularly fragmented data sharing, and inefficient referral processes. By enabling real-time communication, structured referrals, and shared clinical insights, ZEISS Collaborative Care empowers providers to make fast and confident clinical decisions.

ZEISS Collaborative Care

ZEISS Collaborative Care will be demonstrated for the first time at the 100% Optical 2026 congress in London from Feb. 28 to March 2, and then again at the Vision Expo event in Orlando, FL, from March 11 to 14.

“At ZEISS, we’ve focused the strengths of our digital expertise to address some of the persistent challenges in a patient’s healthcare journey. Working closely with our customers, we’ve laid the foundation to transform continuity of care today, supported by data-driven, digital care models that can follow patients throughout their ophthalmic care pathway. ZEISS Collaborative Care is an important step forward in our vision, bringing care teams closer together for more efficient patient care,” says Magnus Reibenspiess, Chief Commercial Officer and Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology.  

A new standard for connected care

ZEISS Collaborative Care is delivered as an application of the ZEISS Healthcare Data Platform (HDP), which provides the secure cloud foundation behind our digital solutions. As an HDP-powered application, it offers flexible deployment for practitioners to support a wide range of clinical environments. Practices may use it as a standalone cloud solution or as a connected extension of ZEISS FORUM allowing diagnostic data, images, and insights to flow seamlessly from on-premises systems into secure, browser-based collaboration spaces. This flexibility ensures providers – regardless of their current digital infrastructure – can participate in efficient, data-driven care pathways.

ZEISS Collaborative Care offers an intuitive set of real-time collaboration tools, ensuring clinical data moves with the patient, supporting better decisions and more coordinated care. It integrates smoothly into existing ZEISS solutions and adheres to industry standard security requirements, enabling eye care professionals to collaborate with confidence.

SHARE – exchange insights and data to enhance decision-making

• Securely exchanging images, reports and patient data to obtain second opinions and foster more confident clinical decision-making.
• Consult with peers on challenging cases to validate assessments and determine the best care pathway for patients.
• Communicate in real-time via chat and stay updated with email notifications.

REFER – streamline referral workflows

• Send, track and prioritize referrals through a user-friendly, secure browser-based application, ensuring the right data gets to the right provider at the right time.
• Facilitate seamless patient care updates between referring and receiving practitioners, optimizing the patient journey from consultation to specialist care.
• Easily receive and download patient data into the eye care professional’s system for comprehensive analysis and documentation.

NETWORK – strengthen professional networks to improve continuity of care

• Build stronger professional connections and trust between optometrists and ophthalmologists, and foster an open network dedicated to better patient care.
• Exchange clinical knowledge and access peer support anytime, anywhere to enhance the eye care professional’s practice.
• Collaborate within a professional network via a browser, independent of any one data management system.

For more information about ZEISS Collaborative Care visit here.

Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals’ content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support.

Contact for investors:
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
Mail: investors.med@zeiss.com

Contact for the press:
Frank Smith
Head of Global Communications
Ophthalmology, Carl Zeiss Meditec Inc.
Phone: +49 3641 220 331
Mail: press.med@zeiss.com

Company Profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,784 employees worldwide, the Group generated revenue of €2,228m in fiscal year 2024/25 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med

Harnessing the vitality of a clone while neutralizing ethical controversies through a breakthrough ‘Therapeutic Cloning’ protocol—ushering in a new era of regenerative medicine to conquer cancer, Alzheimer’s, and aging.

YONGIN, South Korea, Feb. 23, 2026 /PRNewswire/ — Human cloning has long been a subject of dystopian science fiction and a stringent ethical taboo. However, Clonell Therapeutics, Inc., a cutting-edge biotechnology company, is actively shaking the landscape of regenerative medicine by bringing this powerful, historically controversial technology into the clinical setting in an entirely ethical and legal form.

Pioneering the clinical application of human cloning technology, Clonell today officially released a comprehensive therapeutic white paper on its global website (https://www.clonell.com). The white paper details ultimate treatment protocols for 34 conditions currently classified as incurable diseases. The medical community’s attention is highly focused, as the target diseases encompass not only Alzheimer’s disease, Parkinson’s disease, and myocardial infarction, but also cancer and even aging itself.

How can a single technology target such a broad spectrum of diseases simultaneously? According to Clonell’s white paper, the answer lies in precisely targeting ‘Cellular Senescence’—the common underlying culprit behind modern diseases. Moving beyond the limitations of conventional medicine, which has primarily focused on symptom management and suppressing disease progression, Clonell’s approach envisions completely replacing the old, diseased cells that comprise failing organs with young, healthy cells from the patients themselves.

The crucial challenge has always been how to generate these miraculous cells. Here, Clonell has played its most unconventional and transformative card: ‘Human Cloning.’ Cells generated through human cloning technology are a 100% genetic match to the patient, resulting in zero immune rejection. Simultaneously, their biological age is reset to ‘zero,’ granting them the explosive regenerative power observed only in the earliest stages of life. A therapeutic agent satisfying both of these critical conditions has never existed in the history of regenerative medicine.

Dr. Hyo-Sang Lee, currently the Chief Scientific Officer at Clonell and a key protagonist of the Oregon Health & Science University (OHSU) research team that successfully established the world’s first SCNT-hESCs (Somatic Cell Nuclear Transfer-derived Human Embryonic Stem Cells, the original paper) from a cloned human embryo in 2013, stated:

“To fundamentally cure diseased organs, we require cells that our body’s immune system will not reject, while also possessing a youthful vigor strong enough to rebuild the damaged organ. However, apart from human cloning technology, no existing treatment has been able to satisfy both conditions simultaneously. Until now, medicine has always been forced to choose one or the other. The reason degenerative diseases, including aging, have remained unconquered is simply that the cells capable of solving this core dilemma did not exist.”

Does this mean Clonell is creating human clones? Not at all. Clonell’s cloned cells begin with SCNT, the core technology of human cloning, where a patient’s somatic cell is fused with an enucleated oocyte to create a cloned embryo. However, instead of transferring this cloned embryo into a surrogate to create a fully formed human clone—a method known as ‘Reproductive Cloning’—Clonell utilizes a ‘Therapeutic Cloning’ approach. The company extracts cells from the blastocyst after culturing it in a laboratory for seven days. Ultimately, this is a highly intelligent strategy: safely capturing the perfect biocompatibility and biological age-zero vitality of a clone, without ever creating a living, breathing human organism.

Dr. Lee further emphasized, “We have finally found the master key to harness the explosive vitality equivalent to that of a human clone for patient treatment, while strictly adhering to all bioethical standards. Human cloning technology is no longer science fiction or an ethical taboo. It is a highly effective, practical medical tool for fighting incurable diseases and represents the most perfect biological cure humanity has ever dreamed of.”

Detailed disease-specific treatment protocols and mechanisms for the 34 incurable diseases proposed by Clonell are now available to the public and scientific community on the official website (https://www.clonell.com).

About Clonell Therapeutics, Inc.

Clonell™ is a state-of-the-art biotechnology company dedicated to developing fundamental cures for intractable and incurable diseases through human cloning technology (Therapeutic Cloning). Built upon unrivaled technological expertise, the company boasts an extensive therapeutic pipeline addressing neurodegenerative diseases, cardiovascular diseases, and aging-related conditions. With ‘patient-centric innovation’ as its highest core value, Clonell is ushering in a new era of personalized regenerative medicine by introducing an unprecedented paradigm: the ‘Patient-Initiated Clinical Trial™,’ empowering patients to proactively lead the clinical journey for their own cures.

Media Contact Clonell Therapeutics, Inc. Public Relations Email: media@clonell.com

Bitmine has 3,040,483 staked ETH, representing $6.0 billion at $1,958 per ETH; MAVAN staking solution on track to launch Q1 2026

Bitmine now owns 3.66% of the ETH token supply, over 73% of the way to the ‘Alchemy of 5%’ in just 7 months

Bitmine recently closed on initial $200 million investment into Beast Industries

Bitmine Crypto + Total Cash Holdings + “Moonshots” total $9.6 billion, including 4.423 million ETH tokens, total cash of $691 million, and other crypto holdings

Bitmine leads crypto treasury peers by both the velocity of raising crypto NAV per share and by the high trading liquidity of BMNR stock

Bitmine is the 165th most traded stock in the US, trading $0.7 billion per day (5-day avg)

Bitmine remains supported by a premier group of institutional investors including ARK’s Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas “Tom” Lee to support Bitmine’s goal of acquiring 5% of ETH

LAS VEGAS, Feb. 23, 2026 /PRNewswire/ — (NYSE AMERICAN: BMNR) Bitmine Immersion Technologies, Inc. (“Bitmine” or the “Company”) a Bitcoin and Ethereum Network company with a focus on the accumulation of crypto for long term investment, today announced Bitmine crypto + total cash + “moonshots” holdings totaling $9.6 billion.

Bitmine weekly update

As of February 22th, 2026 at 6:00pm ET, the Company’s crypto holdings are comprised of 4,422,659 ETH at $1,958 per ETH (NASDAQ: COIN), 193 Bitcoin (BTC), $200 million stake in Beast Industries, $17 million stake in Eightco Holdings (NASDAQ: ORBS) (“moonshots”) and total cash of $691 million. Bitmine’s ETH holdings are 3.66% of the ETH supply (of 120.7 million ETH).

“In the midst of this ‘mini crypto winter,’ our focus continues to be on methodically executing our treasury strategy and steadily acquiring ETH and in turn, optimizing the yield on our ETH holdings,” said Thomas “Tom” Lee, Chairman of Bitmine.

“We discussed this operational strategy in our latest Chairman’s message (the link to his message is here). While crypto prices are attempting to find their respective lows, the three fundamental drivers for Ethereum continue to gain traction: (i) Wall Street and their efforts at tokenization; (ii) AI and agentic-AI using smart blockchains for both execution and for collecting payments and (iii) the emerging creator economy and their desire to use blockchains for verification,” continued Lee.

“In the past week, we acquired 51,162 ETH,” continued Lee. “Bitmine has been steadily buying Ethereum, as we view this pullback as attractive, given the strengthening fundamentals. In our view, the price of ETH is not reflective of the high utility of ETH and its role as the future of finance.”

As of February 22, 2026, Bitmine total staked ETH stands at 3,040,483 ($6.0 billion at $1,958 per ETH). “Bitmine has staked more ETH than other entities in the world. At scale (when Bitmine’s ETH is fully staked by MAVAN and its staking partners), the ETH staking rewards is $249 million annually (using 2.89% 7-day BMNR yield),” stated Lee.

“Annualized staking revenues are now $171 million. And this 3.0 million ETH is about 69% of the 4.4 million ETH held by Bitmine. The CESR (Composite Ethereum Staking Rate, administered by Quatrefoil) is 2.81%, while Bitmine’s own staking operations generated a 7-day yield of 2.89% (annualized). We continue to make progress on our staking solution known as The Made in America VAlidator Network (MAVAN). This will be the ‘best-in-class’ solution offering secure staking infrastructure and will be deployed in early calendar 2026. Bitmine is currently working with 3 staking providers as the Company moves towards unveiling MAVAN in 2026,” continued Lee.

Bitmine crypto holding reigns as the #1 Ethereum treasury and #2 global treasury, behind Strategy Inc. (NASDAQ: MSTR), which owns 717,131 BTC valued at $49 billion. Bitmine remains the largest ETH treasury in the world. 

Bitmine is one of the most widely traded stocks in the US. According to data from Fundstrat, the stock has traded average daily dollar volume of $0.7 billion (5-day average, as of February 20, 2026), ranking #165 in the US, behind Carnival Corp (rank #164) and ahead of Northrup Grumman (rank #166) among 5,704 US-listed stocks (statista.com and Fundstrat research).

The GENIUS Act and Securities and Exchange Commission’s (“the SEC”) Project Crypto are as transformational to financial services in 2025 as US action on August 15, 1971 ending Bretton Woods and the USD on the gold standard 54 years ago. This 1971 event was the catalyst for the modernization of Wall Street, creating the iconic Wall Street titans and financial and payment rails of today. These proved to be better investments than gold.

The Chairman’s message can be found here:
https://www.Bitminetech.io/chairmans-message

The Fiscal Full Year 2025 Earnings presentation and corporate presentation can be found here:
https://Bitminetech.io/investor-relations/

To stay informed, please sign up at: https://Bitminetech.io/contact-us/

About Bitmine
Bitmine (NYSE AMERICAN: BMNR) is the leading Ethereum Treasury company in the world, implementing an innovative digital asset strategy for institutional investors and public market participants. Guided by its philosophy of “the alchemy of 5%,” the Company is committed to ETH as its primary treasury reserve asset, leveraging native protocol-level activities including staking and decentralized finance mechanisms. The Company will launch MAVAN (Made-in America VAlidator Network), a dedicated staking infrastructure for Bitmine assets, in Q1 of 2026.

For additional details, follow on X:
https://x.com/bitmnr
https://x.com/fundstrat
https://x.com/bmnrintern

Forward Looking Statements
This press release contains statements that constitute “forward-looking statements.” The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. This document specifically contains forward-looking statements regarding progress and achievement of the Company’s goals regarding ETH acquisition and staking, the long-term value of Ethereum, continued growth and advancement of the Company’s Ethereum treasury strategy and the applicable benefits to the Company. In evaluating these forward-looking statements, you should consider various factors, including Bitmine’s ability to keep pace with new technology and changing market needs; Bitmine’s ability to finance its current business, Ethereum treasury operations and proposed future business; the competitive environment of Bitmine’s business; and the future value of Bitcoin and Ethereum. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond Bitmine’s control, including those set forth in the Risk Factors section of Bitmine’s Form 10-K filed with the SEC on November 21, 2025, as well as all other SEC filings, as amended or updated from time to time. Copies of Bitmine’s filings with the SEC are available on the SEC’s website at www.sec.gov. Bitmine undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

STAKING: BMNR now staking over 3 million ETH

ALCHEMY of 5%: BMNR ranked #165 by avg daily $ volume

PARIS, NEW YORK and LONDON, Feb. 23, 2026 /PRNewswire/ — AMTD Group Inc. (“AMTD Group”), AMTD IDEA Group (NYSE: AMTD; SGX: HKB), AMTD Digital Inc. (NYSE: HKD) and The Generation Essentials Group (“TGE”, NYSE: TGE; LSE: TGE), a subsidiary of AMTD Digital Inc., jointly announce that “Scare Out” (the “Movie”), the first ever national‑security film co‑produced by TGE, captured a significant share of the box office during the Chinese New Year window. Featuring an all‑star cast including Jackson Yee, Yilong Zhu, Jia Song, Jiayin Lei, Mi Yang, Yi Zhang, Cecilia Liu, and Yaowen Liu, the Movie achieved box office inflows of over US$120 million within just its first seven days of release.

The Movie has also generated substantial traction on social media. Across major platforms, promotional content related to the Movie has attracted approximately 10.35 billion views, with daily increases of over 550 million views. On Douyin alone, the Movie’s hashtag has reached 5.32 billion views.

“Scare Out” represents a major success for TGE’s movie segment. Looking ahead to the second half of 2026 and into 2027, TGE‑produced films such as “Raging Havoc” and “Dog Day Evening” are scheduled for release. Both projects feature strong casts: “Raging Havoc” stars Andy Lau, Nicholas Tse, and Ci Sha, while “Dog Day Evening” features Michael Ning, Fish Liew, and Rachel Leung. TGE serves as a lead production company on both titles, with Dr. Calvin Choi, founder of AMTD IDEA, AMTD Digital, and TGE, acting as a Producer.

These upcoming releases are expected to further strengthen TGE’s movie portfolio and provide a solid foundation for future growth on a global basis.

TGE’s movie segment also continues to benefit from cross-segment synergies within the group. L’OFFICIEL, under TGE, has become a strategic media partner of the 44th Hong Kong Film Awards, and, with the continuous growth and strong developments of the L’OFFICIEL Movies business segment, is emerging as an important player in Hong Kong’s film media landscape. Internationally, L’OFFICIEL has conducted on-site coverage and interviews at major awards events such as the Golden Globe Awards and the British Academy Film Awards, and is expected to extend our presence at the Oscars this year. TGE will continue to strengthen and expand its global media outreaches and influential power, as a core part of its global media and entertainment IP businesses.

About AMTD Group

AMTD Group is a conglomerate with a core business portfolio spanning across media and entertainment, education and training, and premium assets and hospitality sectors.

About AMTD IDEA Group

AMTD IDEA Group (NYSE: AMTD; SGX: HKB) represents a diversified institution and digital solutions group connecting companies and investors with global markets. Its comprehensive one-stop business services plus digital solutions platform addresses different clients’ diverse and inter-connected business needs and digital requirements across all phases of their life cycles. AMTD IDEA Group is uniquely positioned as an active super connector between clients, business partners, investee companies, and investors, connecting the East and the West. For more information, please visit www.amtdinc.com or follow us on X (formerly known as “Twitter”) at @AMTDGroup.

About AMTD Digital Inc.

AMTD Digital Inc. (NYSE: HKD) is a comprehensive digital solutions platform headquartered in France. Its one-stop digital solutions platform operates key business lines including digital media, content and marketing services, investments as well as hospitality and VIP services. For AMTD Digital’s announcements, please visit https://ir.amtdigital.net/investor-news.

About The Generation Essentials Group

The Generation Essentials Group (NYSE: TGE; LSE: TGE), jointly established by AMTD Group, AMTD IDEA Group (NYSE: AMTD; SGX: HKB) and AMTD Digital Inc. (NYSE: HKD), is headquartered in France and focuses on global strategies and developments in multi-media, entertainment, and cultural affairs worldwide as well as hospitality and VIP services. TGE comprises L’Officiel, The Art Newspaper, movie and entertainment projects. Collectively, TGE is a diversified portfolio of media and entertainment businesses, and a global portfolio of premium properties. Also, TGE is a special purpose acquisition company (SPAC) sponsor manager, with its first SPAC successfully raised and priced on December 18, 2025.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor”provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,””anticipates,” “aims,” “future,” “intends,” “plans,” “believes,””estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about the beliefs, plans, and expectations of AMTD IDEA Group, AMTD Digital and/or The Generation Essentials Group, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in the filings of AMTD IDEA Group, AMTD Digital and The Generation Essentials Group with the SEC. All information provided in this press release is as of the date of this press release, and none of AMTD IDEA Group, AMTD Digital and The Generation Essentials Group undertakes any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

For AMTD IDEA Group:
IR Office
AMTD IDEA Group
EMAIL: ir@amtdinc.com

For AMTD Digital Inc.:
IR Office
AMTD Digital Inc.
EMAIL: ir@amtdigital.net

For The Generation Essentials Group:
IR Office
The Generation Essentials Group
EMAIL: ir@tge.media